Get the Stockscreener App
0.7142
33.74%
0.1802
Brainstorm Cell Therapeutics Inc stock is traded at $0.7142, with a volume of 10,941.
It is up +33.74% in the last 24 hours and up +33.74% over the past month.
BRAINSTORM CELL THERAPUTC
See More
Previous Close:
$0.534
Open:
$0.68
24h Volume:
10,941
Relative Volume:
11.75
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-0.595
EPS:
-1.2003
Net Cash Flow:
$-6.98M
1W Performance:
+33.74%
1M Performance:
+33.74%
6M Performance:
-68.49%
1Y Performance:
-87.10%
1-Day Range:
$0.68
$0.789
1-Week Range:
$0.68
$0.789
52-Week Range:
$0.534
$0.789
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare BCLI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.7142 | 0 | 0 | -10.31M | -6.98M | -1.2003 |
VRTX
Vertex Pharmaceuticals Inc
|
448.56 | 110.97B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
623.78 | 65.81B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
840.60 | 51.03B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.31 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.16 | 32.53B | 742.00K | -1.37B | -1.07B | -7.0731 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
BrainStorm adds ex-FDA official to board ahead of ALS trial - Investing.com Australia
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - PR Newswire
7.8M Brainstorm (OTCQB: BCLI) shares registered for warrant-linked resale - Stock Titan
BrainStorm Cell (BCLI) director receives 150,000 stock options at $0.70 strike - Stock Titan
BrainStorm Cell (BCLI) director granted 150K options at $0.70 strike - Stock Titan
BRAINSTORM CELL (BCLI) director receives 225,000 stock options at $0.70 strike - Stock Titan
Brainstorm Cell (BCLI) director receives grant of 150,000 stock options at $0.70 - Stock Titan
BrainStorm Cell (BCLI) grants director Naor Nir 180K stock options - Stock Titan
[Form 4] BRAINSTORM CELL THERAPEUTICS INC. Insider Trading Activity - Stock Titan
BrainStorm raises $400,000 in May private placement at premium By Investing.com - Investing.com South Africa
BrainStorm raises $400,000 in May private placement at premium - Investing.com
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market - StreetInsider
Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market - Moomoo
BrainStorm reports Q1 2026 loss but advances Phase 3 trial for ALS treatment NurOwn. - Pluang
BrainStorm Cell Therapeutics posts $2.1M quarterly net loss, cash ~$0.2M as of Mar 31, 2026 - TradingView
BrainStorm Cell (OTCQB: BCLI) posts Q1 2026 loss and details NurOwn ALS plans - Stock Titan
Brainstorm Cell Therapeutics announces first quarter 2026 financial results and provides corporate update - marketscreener.com
Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update - TradingView
BRAINSTORM CELL THERAPEUTICS INC. 1Q 2026: Net income $(2.13M), EPS $(0.19) — 10-Q Summary - TradingView
Brainstorm Cell (BCLI) Q1 2026 loss deepens going-concern pressures - Stock Titan
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Brainstorm Cell Therapeutics (BCLI) Eps Diluted (TTM) - Zacks Investment Research
MSN Money - MSN
Brainstorm Cell Therapeutics Inc. announced that it has received $0.2 million in funding - marketscreener.com
Brainstorm Cell Therapeutics Inc. announced that it expects to receive $0.2 million in funding - marketscreener.com
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Quantisnow
BCLI SEC FilingsBrainstorm Cell Therapeutics I 10-K, 10-Q, 8-K Forms - Stock Titan
Top Synthetic Stem Cells MarketAthersys, Inc., BrainStorm - openPR.com
Leading Companies Reinforcing Their Presence in the Stem Cell Therapy for Multiple Sclerosis Market - openPR.com
Aug Shorts: What is the target price for Brainstorm Cell Therapeutics Inc stockMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Whats the profit margin of Brainstorm Cell Therapeutics IncGold Moves & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Brainstorm Cell Therapeutics Inc. (BCLI) Stock Price | Live Quotes & Charts | OTCQB - StocksToTrade
Brainstorm Cell Therapeutics 2025 10-K: $0.0M Revenue, $(1.11) EPS - TradingView — Track All Markets
ALS therapy pivot: BrainStorm (BCLI) pulls BLA, wins FDA SPA for new Phase 3b - Stock Titan
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BrainStorm Cell (OTCQB: BCLI) posts 2025 loss, tight cash and equity deficit - Stock Titan
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - ChartMill
Growth Value: What is the target price for Brainstorm Cell Therapeutics Inc stock2026 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Gap Down: Whats the profit margin of Brainstorm Cell Therapeutics Inc2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Pullback Watch: Is Brainstorm Cell Therapeutics Inc in a long term uptrend2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Breakout Zone: Does Brainstorm Cell Therapeutics Inc have declining or rising EPS2026 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® - Nasdaq
If You Invested $1,000 in Brainstorm Cell Therapeutics I (BCLI) - Stock Titan
Tech Rally: Is Brainstorm Cell Therapeutics Inc stock risky to hold nowEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 Delveinsight Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - menafn.com
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Insider Buy: Is Olema Pharmaceuticals Inc forming bullish engulfing patterns2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: How do insiders feel about Brainstorm Cell Therapeutics Inc2026 Short Interest & Community Trade Idea Sharing - baoquankhu1.vn
Maxim Group downgrades Brainstorm Cell Therapeutics (BCLI) - MSN
S P Trends: Is Brainstorm Cell Therapeutics Inc in a long term uptrend2025 Top Gainers & Weekly Breakout Watchlists - baoquankhu1.vn
BCLI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.14%
Cap:
|
Volume (24h):